BristolMyers posts
FeedPosted Nov 9th 2007 3:40PM by Eric Buscemi (RSS feed)
Filed under: Earnings reports, Forecasts, Law, Conventions and conferences, Annual meetings, Wal-Mart (WMT), Home Depot (HD), Bristol-Myers Squibb (BMY), Charles Schwab Corp (SCHW), , Tyson Foods'A' (TSN), Economic data
.gif)
Monday, November 12
- Veterans' Day holiday.
- Tyson Foods (NYSE: TSN) to report Q4 earnings. They are holding a conference call at 9am and a business update later at 10:45am.
Tuesday, November 13
- Wal-Mart Stores (NYSE: WMT) to report Q3 earnings; pre-recorded conference call at 7am.
- Home Depot (NYSE: HD) to report Q3 earnings; conference call at 9am.
- Fed Reserve Governor Randall Kroszner is the Keynote Speaker at Standard & Poor's Banking Conference in New York at 1pm.
Wednesday, November 14
- Fed Reserve Chairman Ben Bernanke is the Keynote Speaker at Cato Institute Annual Monetary Conference at 9:10am.
- Macy's (NYSE: M) to report Q3 earnings; conference call at 10:30am.
Thursday, November 15
Friday, November 16
Posted Jun 19th 2007 11:20AM by Paul Foster (RSS feed)
Filed under: Yahoo! (YHOO), Apple Inc (AAPL), eBay (EBAY), Bristol-Myers Squibb (BMY), UAL Corp (UAUA), Options
eBay(NASDAQ:EBAY) volatility & share price are flat as Meg Whitman has been eBay for nine years. eBay is expected to report EPS in mid July. Goldman has a Buy rating with a $43 price target on eBay. Meg Whitman joined eBay in 1988. Years ago Whitman's said she would leave after eight to ten years. Meg Whitman has an estimated net worth of $1.2 billion according to Forbes, much of it in eBay stock. eBay's share price has underperformed Yahoo Inc.(NYSE:YHOO) over the last four years. eBay over all option implied volatility of 33 is near its 26-week average according to Track Data, suggesting flat risk.
Bristol-Myers(NYSE:BMY) implied volatility Elevated prior to a judge's ruling. BMY is recently trading at $31.92 in pre-open trading, above its close of $30.31. Dow Jones reported "US Judge rejects bid by Apotex to invalidate Plavix patent." BMY received priority review for investigational oncology treatment Ixabepilone (treatment designed to inhibit the growth or development of cancer cells). BMY over all option implied volatility of 26 is above its 26-week average of 23 according to Track Data, indicating larger risk.
Option volume leaders today are: Yahoo (NASDAQ-:YHOO), United Airlines (NASDAQ:UAUA) and Apple (NASDAQ:AAPL).
Daily Option Update is provided by Stock Options Specialist Paul Foster of theflyonthewall.com.
Posted Apr 30th 2007 10:58AM by Kevin Shult (RSS feed)
Filed under: Before the bell, Analyst upgrades and downgrades, Good news, Bristol-Myers Squibb (BMY), Ciena Corp (CIEN), Colgate-Palmolive (CL), Contl Airlines'B' (CAL)
MOST NOTEWORTHY: RF Micro Devices, Inc (RFMD), Bristol-Myers Squibb Co (BMY), Colgate-Palmolive Co (CL), EarthLink. Inc (ELNK) and Hutchinson Technology Inc (HTCH) were today's more noteworthy upgrades:
- CIBC upgraded shares of RF Micro Devices Inc (NASDAQ: RFMD) to Sector Outperformer from Sector Performer as the firm expects the company to benefit from improving late CY07 trends.
- Deutsche Bank upgraded shares of Bristol-Myers Squibb Co (NYSE: BMY) as the firm believes strong Q1 results suggest sustained earnings recovery may be ahead.
- AG Edwards believes Colgate's (NYSE: CL) cost cutting efforts have been paying off, creating a greater "position of strength" for the company, upgrading shares of to Buy from Hold.
- Cowen raised EarthLink Inc (NASDAQ: ELNK) to Neutral from Underperform, believing downside was limited given core business cash flow.
- Hutchinson Technology Inc (NASDAQ: HTCH) was upgraded to Hold from Sell at W.R. Hambrecht, believing their thesis has played out and that further risks to estimates are priced into shares at current levels...
OTHER UPGRADES:
- Ciena Corp (NASDAQ: CIEN) was upgraded to Overweight from Market Weight at Thomas Wiesel, citing accelerated strength growth specific opportunities and improving sector fundamentals.
- Banc of America raised shares of M&T Bank Corp (NYSE: MTB) to Neutral from Sell.
- Longbow Research upgraded shares of Cummins Inc (NYSE: CMI) to Neutral from Sell.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).Posted Apr 27th 2007 11:13AM by Kevin Shult (RSS feed)
Filed under: Before the bell, Analyst upgrades and downgrades, Bad news, PepsiCo (PEP), Bristol-Myers Squibb (BMY), , Dean Foods (DF), OfficeMax Inc (OMX), Nortel Networks (NT), US Airways Group (LCC), AMR Corp (AMR), Contl Airlines'B' (CAL), UAL Corp (UAUA), JetBlue Airways (JBLU)
MOST NOTEWORTHY: Nortel Networks Corp (NT), Bristol-Myers Squibb Co (BMY) and the select airliners were today's most noteworthy downgrades:
- Goldman cut Nortel Networks (NYSE: NT) to Sell from Neutral as the firm believes shares fully discount a successful execution on the cost restructuring.
- JP Morgan sees few catalysts to drive airline shares higher and has downgraded the following stocks:
OTHER DOWNGRADES:
- Keefe Bruyette downgraded Countrywide Financial Corp (NYSE: CFC) to Underperform from Market Perform, citing the impact of tighter credit standards for the move.
- OfficeMax Inc (NYSE: OMX) was cut to Underperform from Peer Perform at Bear Stearns.
- Matrix USA downgraded PepsiCo, Inc (NYSE: PEP) to Hold from Buy on valuation.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).Posted Mar 1st 2007 11:27AM by Kevin Shult (RSS feed)
Filed under: Before the bell, Analyst upgrades and downgrades, Good news, Apple Inc (AAPL), Exxon Mobil (XOM), Krispy Kreme Doughnuts (KKD), Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY)
MOST NOTEWORTHY: Bristol Myers Squibb Co (BMY), Krispy Kreme Doughnuts Inc (KKD), Martha Stewart Living Omnimedia Inc (MSO) and New Century Financial Corp (NEW) were some of today's more notable upgrades:
- UBS upgraded shares of Bristol Myers Squibb Co (NYSE: BMY) to Buy from Neutral. The firm finds the recent pullback an attractive buying opportunity given the possibility of a takeover approach. The broker also believes BMY will likely win its Plavix patent case.
- CIBC resumed coverage of Krispy Kreme Doughnuts Inc (NYSE: KKD) with a Sector Performer rating, up from its recent Underperformer rating, citing resolutions to numerous accounting and legal issues for the upgrade.
- Morgan Stanley upgraded Martha Stewart Living Omnimedia Inc (NYSE: MSO) to Equal Weight from Underweight.
- Bear Stearns upgraded New Century Financial Corp (NYSE: NEW) to Peer Perform from Underperform saying downside risk is limited to $10-$11, but sees upside if business stabilizes and liquidity improves...
OTHER UPGRADES:
- JP Morgan raised Eaton Vance Corp (NYSE: EV) to Neutral from Underweight to reflect the company's strong fund sales and continued capital returns to shareholders.
- AG Edwards replaced Exxon Mobil Corp (NYSE: XOM) on its Focus Portfolio, adding Chevron Corp (CVX) to reflect the company's improved financial strength and attractive valuation.
- Lehman Brothers upgraded Apple Inc (NASDAQ: AAPL) to Overweight from Equal-Weight with a $105 target based on the recent pullback in shares.
- Friedman Billings raised Hess Corp's (NYSE: HES) rating to Outperform from Market Perform, based on growth reserves and an improving outlook.
- Merrill Lynch upgraded Logitech International SA (NASDAQ: LOGI) to Buy from Neutral.
- Matrix upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold on valuation.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).Posted Sep 11th 2006 9:08PM by Sarah Gilbert (RSS feed)
Filed under: Bad news, Rumors, Management
Bristol-Myers Squibb (NYSE:BMY)'s CEO, Peter R. Dolan and General Counsel, Richard K. Willard, will be fired if the company's board of directors agrees with recommendations from an independent monitor. The Wall Street Journal made the unusual move of posting a "breaking news" notice on its web site in advance of the full story.
While Dolan's self-importance is such that the company's "about us" web page features his name, under "CEO:" as the first (and only managerial) Very Important Detail, he's made such gigantic missteps that a recent article said he had "precious little credibility." His attempts to delay generic competition for Plavix are being investigated by the Justice Department, and he's been responsible for "major financial scandals."
Today's Forbes asks, "Who Could Replace Peter Dolan?" and offers up names such as CFO Andrew Bonfield, Chief Scientific Officer Elliot Sigal (a "dark horse") and Karen Katen, Vice Chairman of Pfizer. We'll provide more details as we see them.